Reprogram Foamy Macrophages. Reverse Atherosclerosis.

Our small molecule therapy restores macrophage function to resolve plaques at the cellular root—beyond lipid lowering.

The Problem: Foamy Cells Drive Disease Progression

Current therapies only manage lipid levels. They cannot restore foam macrophages, the dysfunctional immune cells trapped in plaques, leaving residual risk for heart attack and stroke.

“Removing cholesterol isn't enough if the macrophages stay broken.”

Our Breakthrough Solution

Directly reprograms foam macrophages to functional macrophages
Restores clearance, repair, and homeostasis within plaques
Small molecule drug — orally available, scalable, and IP-protected
Demonstrated efficacy in human tissue models and in vivo validation
Biomarker-guided, de-risked path toward clinical translation

Foam Macrophage to Normal Macrophage Transition

Turning dysfunctional foam cells back into healthy, functional macrophages.

Endorsed by Leaders in Cardiovascular Research

"No one else has achieved true functional reprogramming of foam cells at this level."

"Your data show real potential for plaque stabilization and regression."

From Discovery to Translation

Our team of immunologists and chemists uncovered a druggable axis for restoring macrophage health. Through a targeted small molecule platform, we aim to reverse the biology underlying atherosclerosis, not just its symptoms.

Contact Us to Get More Info

We welcome collaboration and investment inquiries. Reach out to explore potential opportunities.

Or simply email us at 📩 macrophage@bioreprogram.com